Why the study?
Evidence needed to be summarized regarding the perioperative management of patients receiving long-term antiplatelet therapy who require elective surgery or procedures to support guideline development.
Does perioperative continuation or bridging of antiplatelet therapy affect major bleeding and thromboembolism in patients receiving long-term antiplatelet therapy undergoing elective surgery?
Does perioperative continuation or bridging of antiplatelet therapy affect major bleeding and thromboembolism in patients receiving long-term antiplatelet therapy undergoing elective surgery?
Perioperative aspirin continuation increases major bleeding but reduces thromboembolism, while LMWH bridging increases bleeding risk.
Answers are grounded in this paper and cite their sources.
Informs perioperative antiplatelet decisions for elective surgery; extends and updates prior ACCP recommendations with systematic evidence.
Objective: To summarize the available evidence about the perioperative management of patients who are receiving long-term antiplatelet therapy and require elective surgery/procedures. Methods: This systematic review supports the development of the American College of Chest Physicians guideline on the perioperative management of antiplatelet therapy. A literature search of MEDLINE, EMBASE, Scopus and Cochrane databases was conducted from each database's inception to July 16, 2020. Meta-analyses were conducted when possible. Results: In patients receiving long-term antiplatelet therapy and undergoing elective noncardiac surgery, the available evidence did not show a significant difference in major bleeding between a shorter vs longer antiplatelet interruption, with low certainty of evidence (COE). Compared with patients who received placebo perioperatively, aspirin continuation was associated with increased risk of major bleeding (relative risk [RR], 1.31; 95% CI, 1.15-1.50; high COE) and lower risk of major thromboembolism (RR, 0.74; 95% CI, 0.58-0.94; moderate COE). During antiplatelet interruption, bridging with low-molecular-weight heparin was associated with increased risk of major bleeding compared with no bridging (RR, 1.86; 95% CI, 1.24-2.79; very low COE). Continuation of antiplatelets during minor dental and ophthalmologic procedures was not associated with a statistically significant difference in the risk of major bleeding (very low COE). Conclusion: This systematic review summarizes the current evidence about the perioperative management of antiplatelet therapy and highlights the urgent need for further research, particularly with the increasing prevalence of patients taking 1 or more antiplatelet agents.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: